Original Article
Controversy about the use and financing of SYSADOA for osteoarthritis in Spain: An analysis of the scientific-social debate in the media
Controversia en el uso y en la financiación de SYSADOA para la osteoartritis en España: un análisis del debate científico-social en los medios de comunicación
a Departamento de Fisioterapia, Facultad de Enfermería, Fisioterapia y Podología, Universidad de Sevilla, Sevilla, Spain
b Servicio de Medicina Física Rehabilitación y Reumatología, Hospital Universitario Punta de Europa, Cádiz, Spain
c Departamento de Educación Física y Educación, Facultad de Educación, Universidad de Sevilla, Sevilla, Spain
Read
465
Timeswas read the article
106
Total PDF
359
Total HTML
Share statistics
array:24 [ "pii" => "S2173574324001126" "issn" => "21735743" "doi" => "10.1016/j.reumae.2024.09.003" "estado" => "S300" "fechaPublicacion" => "2024-10-01" "aid" => "1768" "copyright" => "The Author(s)" "copyrightAnyo" => "2024" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Reumatol Clin. 2024;20:416-22" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S1699258X24000494" "issn" => "1699258X" "doi" => "10.1016/j.reuma.2024.05.002" "estado" => "S300" "fechaPublicacion" => "2024-10-01" "aid" => "1768" "copyright" => "The Author(s)" "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Reumatol Clin. 2024;20:416-22" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original</span>" "titulo" => "Controversia en el uso y en la financiación de SYSADOA para la osteoartritis en España: un análisis del debate científico-social en los medios de comunicación" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "416" "paginaFinal" => "422" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Controversy about the use and financing of SYSADOA for osteoarthritis in Spain: An analysis of the scientific-social debate in the media" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figura 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1008 "Ancho" => 2107 "Tamanyo" => 158957 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Tweet con más <span class="elsevierStyleItalic">retweets</span> y me gustas obtenido en Twitter®.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Pedro Alfonso Domínguez Vera, Luis Carrasco Páez" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Pedro Alfonso" "apellidos" => "Domínguez Vera" ] 1 => array:2 [ "nombre" => "Luis" "apellidos" => "Carrasco Páez" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2173574324001126" "doi" => "10.1016/j.reumae.2024.09.003" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574324001126?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X24000494?idApp=UINPBA00004M" "url" => "/1699258X/0000002000000008/v1_202410020656/S1699258X24000494/v1_202410020656/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2173574324001114" "issn" => "21735743" "doi" => "10.1016/j.reumae.2024.09.002" "estado" => "S300" "fechaPublicacion" => "2024-10-01" "aid" => "1773" "copyright" => "Sociedad Española de Reumatología (SER), Colegio Mexicano de Reumatología (CMR) and Elsevier España, S.L.U." "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Reumatol Clin. 2024;20:423-39" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Special Article</span>" "titulo" => "Update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological and synthetic targeted therapies in rheumatoid arthritis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "423" "paginaFinal" => "439" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Actualización del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas y sintéticas dirigidas en la artritis reumatoide" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 4073 "Ancho" => 2458 "Tamanyo" => 732442 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0070" "detalle" => "Fig. " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Rheumatoid arthritis treatment algorithm.</p> <p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">DMARD: disease-modifying drug. B: biologic. CS: Conventional synthetic. AMO: Another mechanism of action.</p> <p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">JAKi: Janus kinase inhibitor*: Limit the use of JAKi in patients of 65 years and over; those with risk factors for cardiovascular or thromboembolic disease; smokers; or those with additional risk factors for cancer.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "José María Álvaro-Gracia Álvaro, Petra Díaz del Campo Fontecha, José Luis Andréu Sánchez, Alejandro Balsa Criado, Rafael Cáliz Cáliz, Isabel Castrejón Fernández, Hèctor Corominas, José A. Gómez Puerta, Sara Manrique Arija, Natalia Mena Vázquez, Ana Ortiz García, Chamaida Plasencia Rodríguez, Lucía Silva Fernández, Jesús Tornero Molina" "autores" => array:14 [ 0 => array:2 [ "nombre" => "José María" "apellidos" => "Álvaro-Gracia Álvaro" ] 1 => array:2 [ "nombre" => "Petra" "apellidos" => "Díaz del Campo Fontecha" ] 2 => array:2 [ "nombre" => "José Luis" "apellidos" => "Andréu Sánchez" ] 3 => array:2 [ "nombre" => "Alejandro" "apellidos" => "Balsa Criado" ] 4 => array:2 [ "nombre" => "Rafael" "apellidos" => "Cáliz Cáliz" ] 5 => array:2 [ "nombre" => "Isabel" "apellidos" => "Castrejón Fernández" ] 6 => array:2 [ "nombre" => "Hèctor" "apellidos" => "Corominas" ] 7 => array:2 [ "nombre" => "José A." "apellidos" => "Gómez Puerta" ] 8 => array:2 [ "nombre" => "Sara" "apellidos" => "Manrique Arija" ] 9 => array:2 [ "nombre" => "Natalia" "apellidos" => "Mena Vázquez" ] 10 => array:2 [ "nombre" => "Ana" "apellidos" => "Ortiz García" ] 11 => array:2 [ "nombre" => "Chamaida" "apellidos" => "Plasencia Rodríguez" ] 12 => array:2 [ "nombre" => "Lucía" "apellidos" => "Silva Fernández" ] 13 => array:2 [ "nombre" => "Jesús" "apellidos" => "Tornero Molina" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S1699258X24000676" "doi" => "10.1016/j.reuma.2024.05.007" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1699258X24000676?idApp=UINPBA00004M" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173574324001114?idApp=UINPBA00004M" "url" => "/21735743/0000002000000008/v1_202410110607/S2173574324001114/v1_202410110607/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S217357432400114X" "issn" => "21735743" "doi" => "10.1016/j.reumae.2024.09.005" "estado" => "S300" "fechaPublicacion" => "2024-10-01" "aid" => "1766" "copyright" => "Sociedad Española de Reumatología (SER), Colegio Mexicano de Reumatología (CMR) and Elsevier España, S.L.U." "documento" => "article" "crossmark" => 1 "subdocumento" => "fla" "cita" => "Reumatol Clin. 2024;20:409-15" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Frailty assessment in patients with Behçet's syndrome: A cross-sectional monocentric study" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "409" "paginaFinal" => "415" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Evaluación de la fragilidad en pacientes con síndrome de Behçet: un estudio monocéntrico transversal" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1644 "Ancho" => 1560 "Tamanyo" => 122094 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Frailty and components of frailty in patients with BS. (A) Patients according to frailty classification based on Fried frailty phenotype. (B) Frequency of individual frailty components based on the Fried frailty phenotype.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Hakan Apaydin, Serdar Can Güven, Rezan Koçak Ulucaköy, Hakan Babaoğlu, Esra Kayacan Erdoğan, Kevser Orhan, Berkan Armağan" "autores" => array:7 [ 0 => array:2 [ "nombre" => "Hakan" "apellidos" => "Apaydin" ] 1 => array:2 [ "nombre" => "Serdar Can" "apellidos" => "Güven" ] 2 => array:2 [ "nombre" => "Rezan" "apellidos" => "Koçak Ulucaköy" ] 3 => array:2 [ "nombre" => "Hakan" "apellidos" => "Babaoğlu" ] 4 => array:2 [ "nombre" => "Esra" "apellidos" => "Kayacan Erdoğan" ] 5 => array:2 [ "nombre" => "Kevser" "apellidos" => "Orhan" ] 6 => array:2 [ "nombre" => "Berkan" "apellidos" => "Armağan" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S217357432400114X?idApp=UINPBA00004M" "url" => "/21735743/0000002000000008/v1_202410110607/S217357432400114X/v1_202410110607/en/main.assets" ] "en" => array:19 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original Article</span>" "titulo" => "Controversy about the use and financing of SYSADOA for osteoarthritis in Spain: An analysis of the scientific-social debate in the media" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "416" "paginaFinal" => "422" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Pedro Alfonso Domínguez Vera, Luis Carrasco Páez" "autores" => array:2 [ 0 => array:4 [ "nombre" => "Pedro Alfonso" "apellidos" => "Domínguez Vera" "email" => array:1 [ 0 => "peddomver@alum.us.es" ] "referencia" => array:4 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] 3 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Luis" "apellidos" => "Carrasco Páez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Departamento de Fisioterapia, Facultad de Enfermería, Fisioterapia y Podología, Universidad de Sevilla, Sevilla, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Medicina Física Rehabilitación y Reumatología, Hospital Universitario Punta de Europa, Cádiz, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Departamento de Educación Física y Educación, Facultad de Educación, Universidad de Sevilla, Sevilla, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Controversia en el uso y en la financiación de SYSADOA para la osteoartritis en España: un análisis del debate científico-social en los medios de comunicación" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1417 "Ancho" => 2350 "Tamanyo" => 174276 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Number of tweets and interactions per year obtained on Twitter®.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Osteoarthritis (OA) is one of the most common rheumatic diseases in the adult population over 45 years of age, affecting more than 500 million people worldwide.<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a> OA is characterised by changes in joint metabolism, affecting both the deterioration of hyaline cartilage and all the other components of the joint. This can lead to the development of joint pain, stiffness, inflammation and disability.<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2,3</span></a> According to the EPISER 2016 prevalence study, 29.35% of the adult population in Spain suffers from osteoarthritis in one or more joints, this being more prevalent in women, and the lumbar spine being the most affected joint.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">4</span></a> OA is considered the third leading cause of years lived with disability and entails high socioeconomic costs for health systems.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">5</span></a> In Spain, it is estimated that the total cost of hip and knee OA is between 1 and 2.5% of GDP.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">6</span></a> The treatment of OA is a challenge for health professionals, since there is no cure for the disease. Current treatments focus on non-pharmacological, pharmacological and surgical approaches, the latter being recommended when conservative treatment is ineffective and where there is a major impact on quality of life.<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">7,8</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">In this direction, the use of a group of drugs known as SYSADOAs (<span class="elsevierStyleItalic">SYmptomatic Slow-Acting Drugs for Osteoarthritis</span>) has been proposed as a therapy option for the treatment of pain, stiffness and functional capacity in OA.<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">9,10</span></a> However, although there is widespread use in Spain of SYSADOAs drugs such as glucosamine (GS) and chondroitin sulphate (CS), their efficacy and safety have been the subject of controversy in the scientific literature in recent years.<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">11</span></a> On the one hand, some studies have suggested that SYSADOAs may be effective in the treatment of OA, especially in terms of reducing pain, improving joint function, and reducing the consumption of anti-inflammatory drugs.<a class="elsevierStyleCrossRefs" href="#bib0060"><span class="elsevierStyleSup">12,13</span></a> On the other hand, several systematic reviews have questioned the efficacy of SYSADOAs, suggesting that they may have modest or no effects on pain and joint function.<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">14,15</span></a> Due to the disparity in the results of clinical trials and meta-analyses in the use of GS and CS, there is currently no consensus in the scientific evidence as to their efficacy in improving pain or functionality in people with OA.<a class="elsevierStyleCrossRefs" href="#bib0075"><span class="elsevierStyleSup">15,16</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">In addition to the scientific controversy surrounding the efficacy of SYSADOAs, there is also a debate across the media over the financing of these treatments by the Spanish National Health System (SNS in its Spanish acronym). At the end of 2019, the Directorate General for the Common Portfolio of SNS and Pharmacy Services (DGCCSyF), under the Ministry of Health, began the processes of defunding these drugs. Since then, patient associations, the Spanish Society of Health Professionals and civil society have all spoken out through the media, creating a social debate.<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a> In 2020, OAFI (International Osteoarthritis Foundation) initiated legal proceedings with the lodging of an appeal against this de-financing move, which was then temporarily paralysed. Taking into account the importance of recommendations for effective and safe treatments for OA,<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">18</span></a> and the relevance of health-related information in the media,<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">19</span></a> this study aims to qualitatively and quantitatively analyse the controversy over the use and financing of SYSADOAs drugs for OA patients in the Spanish mainstream media and social networks. In addition, another of its purposes is to describe the main positions of public bodies, professional societies and patient organisations.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Methodology</span><p id="par0020" class="elsevierStylePara elsevierViewall">This study was based, on the one hand, on the analysis of the content of articles published in the press, posts in digital media, statements from public bodies and posts on social networks from the 1st of January 2018 to the 1st of January 2023.</p><p id="par0025" class="elsevierStylePara elsevierViewall">In relation to the search for articles in the press, a search was carried out in the 5 generalist newspapers with the highest number of readers in Spain in 2021, according to the General Media Study by the AIMC (Spanish Association for Media Research, 2021). The search was run in both the digital and print versions of the 5 selected newspapers, including the supplements of each newspaper. To this end, the search was undertaken through the MyNews tool, a digital newspaper library belonging to the Spanish press. The keywords used were "osteoarthritis", "SYSADOA", "arthrosis", "treatment", "financing" and "drug", in different combinations using the Boolean operators AND and OR. Articles were included in the study if they met the following criteria: 1) they provided information in the title, subtitle, or body of the article concerning OA and the use of SYSADOAs in OA disease; and 2) they provided information or expressed an opinion on the financing process of SYSADOAs drugs in Spain. In order to establish the position of the articles included on the financing of SYSADOAs by the SNS, these were classified into the following 3 categories:<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">A)</span><p id="par0030" class="elsevierStylePara elsevierViewall">Partial and in favour. When the content of the article offers information and arguments exclusively in favour of financing without providing information on contrary positions.</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">B)</span><p id="par0035" class="elsevierStylePara elsevierViewall">Impartial. When the content of the article expresses positions and information both in favour of and against funding from different points of view.</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">C)</span><p id="par0040" class="elsevierStylePara elsevierViewall">Partial and against. When the content of the article contains information and arguments exclusively against funding, without providing information on positions in favour.</p></li></ul></p><p id="par0045" class="elsevierStylePara elsevierViewall">In relation to social networks, a search was designed for Twitter® by compiling tweets related to the use and financing of SYSADOAs in Spain. To do this, an account was created for this purpose and the advanced search tool of the application itself was used. The same keywords as those used in the press were applied as well as the same temporary filter. In relation to the information provided by non-profit public bodies, we included posts from associations, foundations and public organisations figuring in the census by either the Spanish Ministry of the Interior or the Ministry of Justice. Likewise, for these posts, the same inclusion criteria were maintained.</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Results</span><p id="par0050" class="elsevierStylePara elsevierViewall">The search through the newspaper archives and records of the generalist media examined identified 46 potential articles. Following the rejection of duplicate articles using the <span class="elsevierStyleItalic">MyNews tool,</span> thirty-six articles were analysed for inclusion. Finally, a total of 15 articles that met the established inclusion criteria were accepted. These articles had been published between the 1st of January 2018 and the 1st of January 2023. Regarding the particular sources, 5 articles were published in <span class="elsevierStyleItalic">La Vanguardia</span>, 5 in <span class="elsevierStyleItalic">20minutos</span>, 3 in <span class="elsevierStyleItalic">ABC</span>, 1 in <span class="elsevierStyleItalic">El País</span> and 1 in <span class="elsevierStyleItalic">El Mundo</span>. The articles included in this study were described and summarised according to the media outlet where they were published; the title; the sources used; and the content (whether or not they recommended the use of SYSADOAs in OA, and the position on funding by the Spanish NHS) (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>). It was observed that two-thirds of the articles included were published in <span class="elsevierStyleItalic">La Vanguardia</span> and <span class="elsevierStyleItalic">20minutos</span>, in the same proportion. Regarding the sources used by the articles, 64% were health professionals specialising in the field, of which all belonged to the professional category of medicine. Among the profiles of medical specialisation found, the most frequent specialty was pharmacology (43.7%), followed by rheumatology (25%). On the other hand, the public bodies most consulted as a source were: 24% the OAFI; 16% the Spanish Association with Osteoporosis and Osteoarthritis (AECOSAR), 16% the Ministry of Health; 4% the Spanish Patients' Forum (FEP); 4% the Spanish Society of Pharmacology (SEF) and 4% the Spanish Society of Rheumatology (SER). Only 2 of the articles included used previously published scientific studies as their main reference. The first scientific article cited was the <span class="elsevierStyleItalic">ArtRoCad</span> study, which was used to recommend the use of SYSADOAs on the basis that only 5% of the cost of treating osteoarthritis in Spain corresponded to these drugs.<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">20</span></a> The second study cited was a report prepared by the Ministry of Health in 2014 through the Spanish Network of Agencies for the Assessment of Technologies and Services under the National Health System (RedETS) and the Basque Country’s regional Department of Health, which concluded that international recommendations based on the available scientific evidence justify the process of divestment and the non-recommendation of the use of SYSADOAs in the treatment of OA in hip and knee.<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">21</span></a> Finally, a systematic review and meta-analysis carried out by the <span class="elsevierStyleItalic">European Alliance of Associations for Rheumatology</span> (EULAR), which included 24 reviews and 150 articles, concluded that GS supplementation presented low/moderate evidence with little impact on pain and functional capacity.<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">22</span></a> In relation to the position of articles included in the media on the use and financing of SYSADOA, 73.3% recommended its use; 20% recommended its use, albeit warning of the moderate degree of evidence, little effect, and as a therapeutic alternative; while one article (6.6%) did not recommend its use due to the lack of scientific evidence. Regarding funding, 40% of the articles were classified as partial and in favour (3 in <span class="elsevierStyleItalic">La Vanguardia</span>, 2 in <span class="elsevierStyleItalic">20minutos</span> and one in <span class="elsevierStyleItalic">ABC</span>) and 33.3% as impartial (2 in <span class="elsevierStyleItalic">ABC</span>, one in <span class="elsevierStyleItalic">El País</span>, one in <span class="elsevierStyleItalic">La Vanguardia</span> and one in <span class="elsevierStyleItalic">20minutos</span>). A total of 26.7% of the articles (2 in <span class="elsevierStyleItalic">20minutos</span>, one in <span class="elsevierStyleItalic">El Mundo</span> and one in <span class="elsevierStyleItalic">La Vanguardia</span>) did not provide information or describe positions on the financing of SYSADOA. No article was identified that presented information exclusively against the financing of SYSADOAs by the NHS.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0055" class="elsevierStylePara elsevierViewall">Through the search on the social network Twitter®, 1075 <span class="elsevierStyleItalic">tweets</span> were identified during the same period of inclusion as in the general media. The information was recorded using the Microsoft Excel® spreadsheet programme, after eliminating duplicate <span class="elsevierStyleItalic">tweets</span>, with advertising content and those made in a language other than Spanish, thus leaving a total of 872 <span class="elsevierStyleItalic">tweets</span> obtained for analysis. The <span class="elsevierStyleItalic">tweets</span> obtained by author, date of post, content of the message, number of replies, likes and <span class="elsevierStyleItalic">retweets</span> were analysed. The annual distribution of <span class="elsevierStyleItalic">tweets</span> published and the number of global interactions can be seen in <a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>. A total of 47.9% of tweets were published during 2020. Due to the large number of posts, the 5 accounts with the greatest activity and the most interactions were identified to facilitate the contextualization of the results (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>). The account with the highest activity was @stopatrosis, which accounted for 42.6% of the <span class="elsevierStyleItalic">tweets</span> obtained, 4 times higher than the <span class="elsevierStyleItalic">tweets</span> published by the second most active account. The @stopatrosis profile does not identify anyone personally: it defines itself as an account for the dissemination of OA prevention and the <span class="elsevierStyleItalic">tweets</span> are focussed on the use and vindication of SYSADOAs funding. The @consalud_es account was the second most active account, corresponding to one of the main online newspapers in the health sector: Consalud.es, which belongs to Mediforum (a business group whose main client is the pharmaceutical industry).<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">23</span></a> The third most active account was @condronews, an information account on news and research on OA, belonging to Laboratorios Reig Jofre S.A; these laboratories manufacture SYSADOAs drugs, among other products. The fourth most active account was that of the user Carmen Arpón Domínguez @fabulosa1962, a retired nurse from the Rioja Regional Health Service (SERIS). These 4 most active accounts shared messages in favour of SYSADOAs funding. However, the fifth most active account, @musicaypaz5011, posted messages against the funding and use of SYSADOA. This profile did not present any personal data on identification. Subsequently, this user was contacted by messaging and was asked if he/she wanted to identify their public profile. The user reported that their profession was that of a doctor, without providing any more identification data or affiliation. On the other hand, the tweet with the greatest repercussion and impact was for funding, arguing in favour of the economic expense being passed on to OA patients (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>).</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0060" class="elsevierStylePara elsevierViewall">Regarding the communications by public bodies, a total of 7 documents were identified. We obtained 4 manifestos against defunding SYSADOA, signed jointly by OAFI, FEP, AECOSAR, the General Alliance of Patients (AGP), the Galician Rheumatology League (LRG), and Conarthritis. In addition, 2 communiqués from the Ministry of Health responding to questions posed in the Senate by the Popular Party parliamentary group and a communiqué issued by the OAFI.</p><p id="par0065" class="elsevierStylePara elsevierViewall">To facilitate the understanding and contextualization of the defunding process, the results obtained were graphically synthesised and presented in the form of a timeline (<a class="elsevierStyleCrossRef" href="#fig0015">Fig. 3</a>).</p><elsevierMultimedia ident="fig0015"></elsevierMultimedia></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Discussion</span><p id="par0070" class="elsevierStylePara elsevierViewall">The objective of this study was to analyse the controversy over the use and financing of SYSADOAs in OA patients by Spain`s SNS, both in the general media and in social networks. Together, the main events and positions on this controversy by the most relevant public bodies and associations of patients and professionals were summarised chronologically. To this end, a total of 15 articles from media outlets from <span class="elsevierStyleItalic">ABC</span>, <span class="elsevierStyleItalic">El País</span>, <span class="elsevierStyleItalic">El Mundo</span>, <span class="elsevierStyleItalic">La Vanguardia</span> and <span class="elsevierStyleItalic">20minutos</span> were analysed, as well as 872 public <span class="elsevierStyleItalic">tweets</span> from the social network Twitter® and 7 communiqués from public bodies, professional associations and scientific societies. Regarding the results shown in the press articles analysed, more than 90% of the articles recommended the use of SYSADOA, although 20% of these referred to the controversy over its use due to the scientific evidence shown by these drugs and the limited use when there were no therapeutic alternatives. This majority position recommending the use of SYSADOAs in the general media is far removed from the current discrepancy in the scientific community regarding their use in OA.<a class="elsevierStyleCrossRefs" href="#bib0055"><span class="elsevierStyleSup">11,17,21,24</span></a> The UK’s <span class="elsevierStyleItalic">National Institute for Health and Care Excellence</span> (NICE) clinical guideline on the management of OA did not recommend the use of SYSADOAs due to the scant evidence of GS, CS, and diacerein for this disease.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">8</span></a> Accordingly, a few years earlier, EULAR published a guideline with recommendations in which it considered the use of SYSADOAs to be a recommendation with low to moderate evidence, with a moderate impact on pain and functional capacity in patients with OA of the hand.<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">7</span></a> On the other hand, a clinical guideline published in 2019 by the <span class="elsevierStyleItalic">European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis</span> (ESCEO) considered the use of SYSADOAs as a first line pharmacological treatment in patients with OA of the knee.<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">25</span></a> In relation to the sources used by the articles, it should be noted that only 2 articles used references to scientific studies. The scarce use of references to scientific studies as a source and the absence of contrast with the opposing parties may explain these results.</p><p id="par0075" class="elsevierStylePara elsevierViewall">Regarding the position of the articles that we included against the financing of SYSADOAs by the SNS, 40% were in favour of funding. No articles were identified against funding but only a third of all articles were considered impartial, offering information and arguments both for and against. We consider these results relevant in view of the major impact that the general press has on public opinion concerning health issues.<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">26</span></a></p><p id="par0080" class="elsevierStylePara elsevierViewall">With regard to the results obtained on the social network Twitter®, a similar trend towards support for SYSADOAs funding was observed. Although the total number of tweets published in the last 5 years are mostly in favour, 3 of the 5 accounts (@JuanGrvas, @je_pala and @ceciliacalpi) with the most likes and <span class="elsevierStyleItalic">retweets</span> were against funding by the SNS. This discrepancy can be explained if we look at the account with the most <span class="elsevierStyleItalic">tweets</span>, likes and <span class="elsevierStyleItalic">retweets</span>: @stopartrosis; which accounts for 42.6% of the total <span class="elsevierStyleItalic">tweets</span> included. This is an anonymous account for circulation and support for the financing of SYSADOAs that publishes almost daily. This account was contacted through messaging to obtain more information about this profile; however, no response was obtained. After further investigation, it was identified that this account also appears on social networks such as Facebook® and initiated a signature collection initiative on the Change platform (<a href="https://www.change.com/">https://www.change.com/</a>) against defunding SYSADOAs (2909 out of 5000 signatures, in April 2023). It is noteworthy that the second and third accounts with most posts (@consalud_es and @condronews) were closely related to the pharmaceutical industry or represented laboratories that produce SYSADOAs drugs. The existence of the great influence of marketing from the pharmaceutical industry on pharmaceutical prescriptions is well-known, however the healthcare professionals who write the prescriptions tend to minimise its influence.<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">27</span></a> Despite this, marketing and the influence exerted by the pharmaceutical industry must be considered in the financing process as one more player to be taken into account in the development, advertising, profitability and sustainability of SYSADOA drugs.<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">28</span></a></p><p id="par0085" class="elsevierStylePara elsevierViewall">As regards the communiqués from public bodies, the main positions of public bodies and companies on the de/financing process have been described. Through the information obtained, we can define 2 large blocks: on the one hand, the Ministry of Health, which has maintained the position of defunding this group of drugs, justified by scientific evidence on their low efficacy and the fact that they are drugs which can be directly advertised to the public in the EU. In particular, SYSADOAs are considered dietary supplements in the United States and other European countries and are not subject to public funding.<a class="elsevierStyleCrossRef" href="#bib0145"><span class="elsevierStyleSup">29</span></a> On the other hand, we have the second block led by the OAFI and other associations (FEP, AECOSAR, AGP, LRG and Conarthritis) in favour of maintaining funding. Together with the latest statement from the OAFI of 18th February 2022, it was reported that the file on the de-funding of SYSADOAs pharmaceuticals had been closed following the appeal lodged.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Conclusions</span><p id="par0090" class="elsevierStylePara elsevierViewall">The use of SYSADOAs for patients with OA continues to raise controversy in the scientific community; the disparity of results in different systematic reviews and meta-analyses, together with the discrepancies in recommendation between leading international clinical guidelines, maintain a state of controversy among health professionals as to their degree of recommendation. However, in the face of this controversy in the literature, there is consensus between foundations and associations of OA patients in Spain which, together with some scientific societies, maintain a position in favour of public funding and the use of SYSADOAs as a pharmacological treatment in patients with OA.</p><p id="par0095" class="elsevierStylePara elsevierViewall">The debate that has arisen since the attempt by the Spanish Ministry of Health to defund these drugs in 2019, until the case was closed due to an appeal being filed in 2022 by the OAFI, has continued to be covered extensively by the general media. The media have maintained a general trend of bias in favour of public funding of these drugs, with foundations, associations, or professionals mostly being used, to a certain extent, as a source of information in favour of the use and funding of SYSADOA. The media exerts a major influence on the population's view of public health issues, as well as serving as a possible tool for large corporations to achieve their objectives and stimulate the demand for products that are sometimes unnecessary for the improvement of health. That is why we consider these results relevant and propose a reflection on health communication models that would enable commercial interests to coexist alongside promoting the values of good health. At the same time, on the social network Twitter®, a large proportion of the posts have marked this trend in favour of funding, partly by accounts related to the pharmaceutical industry, while other dissenting users with fewer posts have presented a higher degree of interactions.</p><p id="par0100" class="elsevierStylePara elsevierViewall">The patient organisations, societies and foundations led by the OAFI have managed to halt the SYSADOAs defunding case opened by the DGCCSyF, under the Spanish Ministry of Health. We consider relevant the coverage by the media and social networks in this process, as regards the mediatisation of this scientific/social debate.</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Funding</span><p id="par0105" class="elsevierStylePara elsevierViewall">This study has not received any external funding.</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Conflict of interest</span><p id="par0110" class="elsevierStylePara elsevierViewall">The authors declare that they have no conflict of any kind.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:12 [ 0 => array:3 [ "identificador" => "xres2269782" "titulo" => "Abstract" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Background and objective" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Discussion and conclusions" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1892465" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres2269781" "titulo" => "Resumen" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Antecedentes y objetivo" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Material y métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Discusión y conclusiones" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1892464" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Methodology" ] 6 => array:2 [ "identificador" => "sec0015" "titulo" => "Results" ] 7 => array:2 [ "identificador" => "sec0020" "titulo" => "Discussion" ] 8 => array:2 [ "identificador" => "sec0025" "titulo" => "Conclusions" ] 9 => array:2 [ "identificador" => "sec0030" "titulo" => "Funding" ] 10 => array:2 [ "identificador" => "sec0035" "titulo" => "Conflict of interest" ] 11 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2024-01-29" "fechaAceptado" => "2024-05-02" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1892465" "palabras" => array:6 [ 0 => "Osteoarthritis" 1 => "Glucosamine" 2 => "Chondroitin sulfate" 3 => "Treatment" 4 => "Social media" 5 => "Health communication" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1892464" "palabras" => array:6 [ 0 => "Osteoartritis" 1 => "Glucosamina" 2 => "Condroitín sulfato" 3 => "Tratamiento" 4 => "Medios de comunicación sociales" 5 => "Comunicación en salud" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Background and objective</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">The use of SYmptomatic Slow-Acting Drugs for Osteoarthritis (SYSADOA) in the treatment of osteoarthritis (OA) has been a topic of debate in the scientific community and public entities regarding their public financing in Spain. The objective of this study was to describe and analyse the main positions of media outlets, public entities, regarding the use and financing of SYSADOA in Spain.</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Methods</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">A qualitative and quantitative analysis of the content regarding the use and financing of SYSADOA was conducted in general media outlets (<span class="elsevierStyleItalic">El País</span>, <span class="elsevierStyleItalic">El Mundo, La Vanguardia, ABC,</span> and <span class="elsevierStyleItalic">20minutos</span>), public statements, and Twitter publications.</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">A total of 15 articles in general media outlets, 872 tweets, and 7 public entity statements were identified. Mostly, media outlets (91%) and social media platforms (78%) exhibited a favorable trend towards funding.</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Discussion and conclusions</span><p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">The use of SYSADOA in OA patients continues to be controversial in the scientific community. However, there is consensus among patient associations in favour of public funding and use as a treatment for OA patients.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Background and objective" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Discussion and conclusions" ] ] ] "es" => array:3 [ "titulo" => "Resumen" "resumen" => "<span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Antecedentes y objetivo</span><p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">El uso los SYSADOA (<span class="elsevierStyleItalic">SYmptomatic Slow-Acting Drugs for Osteoarthritis</span>) en el tratamiento de la osteoartritis (OA) ha sido fuente de debate en la comunidad científica y en entidades públicas con relación a su financiación pública en España. El objetivo principal de este estudio fue describir y analizar las principales posiciones de medios de comunicación y entidades públicas frente al uso y financiación de SYSADOA en España.</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Material y métodos</span><p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Se realizó un análisis cualitativo y cuantitativo del contenido respecto al uso y financiación de SYSADOA en medios generalistas (<span class="elsevierStyleItalic">El País</span>, <span class="elsevierStyleItalic">El Mundo</span>, <span class="elsevierStyleItalic">La Vanguardia</span>, <span class="elsevierStyleItalic">ABC</span> y <span class="elsevierStyleItalic">20minutos</span>), comunicados de organismos públicos y publicaciones en Twitter.</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Resultados</span><p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Se identificaron 15 artículos en medios generalistas, 872 tweets y 7 comunicados de organismos públicos. Mayoritariamente, los datos obtenidos en medios de comunicación (91%) y redes sociales (78%) respaldaron la financiación de SYSADOA.</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Discusión y conclusiones</span><p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">A pesar de la controversia en la comunidad científica, este estudio destaca un consenso en los medios de comunicación y asociaciones a favor de la financiación pública de SYSADOA en pacientes de OA.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Antecedentes y objetivo" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Material y métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Discusión y conclusiones" ] ] ] ] "multimedia" => array:20 [ 0 => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1417 "Ancho" => 2350 "Tamanyo" => 174276 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Number of tweets and interactions per year obtained on Twitter®.</p>" ] ] 1 => array:8 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1008 "Ancho" => 2107 "Tamanyo" => 191978 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0010" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Tweets with the most <span class="elsevierStyleItalic">retweets</span> and likes on Twitter®.</p>" ] ] 2 => array:8 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 692 "Ancho" => 2668 "Tamanyo" => 127539 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0015" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Timeline of the SYSADOA financing process in Spain.</p>" ] ] 3 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0020" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Media \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Article Title \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Source \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Recommendation \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Financing \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">El País</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">"Ministry of Health to stop financing drugs for osteoarthritis" \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Carmen Sánchez (treasurer of the Spanish Association with Osteoporosis and Osteoarthritis [AECOSAR])Francisco Blanco García (Rheumatologist)2 scientific articles \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Use of SYSADOAs to decrease pain and increase functional capacity \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">In favour \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">The World</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Osteoarthritis, the disease suffered by Mario Vaquerizo and 7 million other Spaniards \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Marcos Paulino (Rheumatologist) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Moderate evidence, controversial use of SYSADOAs \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">― \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " rowspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">La Vanguardia</span></td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Ministry of Health to stop funding SYSADOA DRUGS for patients with osteoarthritis: "Their scientific evidence is controversial" \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Ministry of HealthJosep Vergés (Pharmacologist and CEO of OAFI) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Using SYSADOA to decrease pain and increase functional capacity \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">In favour \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Osteoarthritis patients ask that sysadoas not be stopped from funding: "They are our only alternative" \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Josep Vergés (Pharmacologist and CEO of OAFI)María Antonia Robles (President of AECOSAR)José Luis Baquero (Director of the Spanish Patients’ Forum: FEP) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Use of SYSADOAs due to their efficacy, safety, and no available pharmacological alternative \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">In favour \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Experts defend the use of SYSADOA drugs within the first line of treatment for osteoarthritis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Antonio García (Professor of Pharmacology)María Teresa Tejerina (President of the Spanish Society of Pharmacology) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Use of SYSADOAs to decrease pain and increase functional capacity \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">In favour \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Alternatives to treat knee osteoarthritis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Iván Robert Calvet (Traumatologist) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Does not recommend the use of SYSADOAs, due to lack of evidence \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">― \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Those affected by osteoarthritis ask for more research for this neglected disease \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Josep Vergés (Pharmacologist and CEO of OAFI) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Proper Use of SYSADOAs \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">In favour \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " rowspan="3" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">ABC</span></td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Osteoarthritis: "I'm terrified of people shaking my hand" \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">José Luis Pablos (Rheumatologist) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Limited use of SYSADOA, ineffective, only when there is no therapeutic alternative \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Impartial \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Patients with osteoarthritis ask that a group of drugs not be stopped \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">María Antonia Robles (President of AECOSAR) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Use of SYSADOA, especially for its high security against comorbidities \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">In favour \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Health will stop financing a group of drugs against osteoarthritis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Ministry of HealthJosep Vergés (Pharmacologist and CEO of OAFI) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Use of SYSADOA due to its effectiveness and safety \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">In favour \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " rowspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">20minutos</span></td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Protests by patients with osteoarthritis after the decision by the Health Ministry to stop financing a type of medicine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Ministry of Health, Josep Vergés (Pharmacologist and CEO of OAFI) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Use of SYSADOAs due to their safety and effectiveness \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">In favour \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">How diet influences the advance of osteoarthritis and rheumatoid arthritis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">A scientific article \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Moderate evidence for the use of SYSADOAs, with little benefit \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">― \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Osteoarthritis or arthritis, do you know how to differentiate them? \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mercedes Borja (Journalist) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Using SYSADOAs as cartilage protectors \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">― \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">The vulnerability of patients with osteoarthritis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Carmen Sánchez (Treasurer of the Spanish Association with Osteoporosis and Osteoarthritis), SocietySpanish Degree in Rheumatology,Sergio Giménez (Primary Care Physician) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Use of SYSADOAs due to their efficacy, safety, and no available pharmacological alternative \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">In favour \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Ministry of Health to stop funding SYSADOA DRUGS for osteoarthritis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Josep Verges (Pharmacologist and CEO of OAFI)Ministry of Health \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Use of SYSADOAs due to their effectiveness and safety \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">In favour \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3686937.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Classification and summary of the content of articles identified in the general media.</p>" ] ] 4 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULT